Acrobiosystems Co

Acrobiosystems Co SGA/Revenue

The SGA to Revenue Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 17.81 %. In the previous year, SGA to Revenue Ratio was 16.99 % — a change of 4.85% (higher).

SGA/Revenue

17.81 %

YoY

4.85%

Last updated:

SGA to Revenue Ratio of Acrobiosystems Co is 2025 17.81 % . SGA to Revenue Ratio of Acrobiosystems Co was 2024 16.99 % . It decreases by 4.85% higher compared to the previous year.

The Acrobiosystems Co SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2018
45.34 CNY
Jan 1, 2019
13.67 CNY
Jan 1, 2020
9.81 CNY
Jan 1, 2021
14.25 CNY
Jan 1, 2022
15.15 CNY
Jan 1, 2023
17.32 CNY
Jan 1, 2024
16.99 CNY
Jan 1, 2025
17.81 CNY
The Acrobiosystems Co SGA/Revenue history
YEARSGA/RevenueYoY
17.81 %+4.85%
16.99 %-1.94%
17.32 %+14.32%
15.15 %+6.29%
14.25 %+45.30%
9.81 %-28.25%
13.67 %-69.84%
45.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

SGA to Revenue Ratio of Acrobiosystems Co is 17.81 % in 2025.

SGA to Revenue Ratio of Acrobiosystems Co changed from 16.99 % to 17.81 %, representing a 4.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co